CSIMarket Company Name, Ticker, Industry, else..
 
Mimedx Group Inc   (NASDAQ: MDXG)
 

Mimedx Group Inc's Suppliers Performance

MDXG's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
MDXG Costs vs Sales of Suppliers Growth Mimedx Group Inc recorded an increase in cost of sales by 11.01 % year on year, sequentially cost of sales grew by 17.54 % in Q2.

• More on MDXG Suppliers



Mimedx Group Inc recorded increase in cost of sales by 11.01 % year on year, sequentially cost of sales grew by 17.54 % in Q2.

• More on MDXG Suppliers




Mimedx Group Inc's Comment on Supply Chain


The company sources raw materials and operates facilities and equipment in accordance with FDA regulations under 21 CFR Part 1271, which encompass standards for product recovery, distribution, tracking, labeling, and complaint handling. The FDA conducts inspections of manufacturing and contract manufacturing facilities to ensure compliance with Current Good Tissue Practice (CGTP) and may initiate enforcement actions for significant non-compliance. The company monitors FDA guidance, including the 2017 policy framework for regenerative medicine products and a March 2024 FDA determination regarding AXIOFILL, a human-derived particulate wound dressing. The FDA does not classify AXIOFILL under Section 361. The company is legally challenging this determination while continuing to market AXIOFILL during the proceedings.

Mimedx Group Inc's Comment on Supply Chain


The company sources raw materials and operates facilities and equipment in accordance with FDA regulations under 21 CFR Part 1271, which encompass standards for product recovery, distribution, tracking, labeling, and complaint handling. The FDA conducts inspections of manufacturing and contract manufacturing facilities to ensure compliance with Current Good Tissue Practice (CGTP) and may initiate enforcement actions for significant non-compliance. The company monitors FDA guidance, including the 2017 policy framework for regenerative medicine products and a March 2024 FDA determination regarding AXIOFILL, a human-derived particulate wound dressing. The FDA does not classify AXIOFILL under Section 361. The company is legally challenging this determination while continuing to market AXIOFILL during the proceedings.







MDXG's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Mimedx Group Inc 710.90 354.09 6.24 808
SUBTOTAL 0.00 0.00 0.00 -


Sources: Mimedx Group Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Mimedx Group Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.